Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet’s disease: results from a large real-world observational study

Adalimumab Reduces Extraintestinal Manifestations in Patients with Crohn’s Disease: A Pooled Analysis of 11 Clinical Studies

(2018) Edouard J. Louis et al.   ADVANCES IN THERAPY

Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis

(2016) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of adalimumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study

(2016) Claudia Fabiani et al.   CLINICAL RHEUMATOLOGY

Safety of Adalimumab and Predictors of Adverse Events in 1693 Japanese Patients with Crohn’s Disease

(2016) Haruhiko Ogata et al.   Journal of Crohns & Colitis

Adalimumab for the Treatment of Japanese Patients With Intestinal Behçet’s Disease

(2015) Satoshi Tanida et al.   Clinical Gastroenterology and Hepatology

An update on the diagnosis, treatment, and prognosis of intestinal Behçetʼs disease

(2015) Jae Hee Cheon et al.   CURRENT OPINION IN RHEUMATOLOGY

Approaches to immunosuppression in Behçet’s disease

(2013) Cloé Comarmond et al.   Immunotherapy

Behcet′s disease in India: A dermatological perspective

(2013) Archana Singal et al.   Indian Journal of Dermatology Venereology & Leprology

The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet’s disease: indication of anti-TNFα monoclonal antibodies

(2013) Tadakazu Hisamatsu et al.   JOURNAL OF GASTROENTEROLOGY

Outcome Predictors for Intestinal Behçet's Disease

(2013) Jae Jun Park et al.   YONSEI MEDICAL JOURNAL

Behçet's disease

(2012) David Saadoun et al.   Orphanet Journal of Rare Diseases

Adalimumab for the treatment of Behcet's disease: experience in 19 patients

(2012) D. Perra et al.   RHEUMATOLOGY

Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn’s disease

(2011) M. A. Kamm et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohnʼs disease: Results from CARE

(2011) Robert Löfberg et al.   INFLAMMATORY BOWEL DISEASES

Behçet Disease

(2011) Haruko Ideguchi et al.   MEDICINE

Clinical Experience with Adalimumab in the Treatment of Ocular Behçet Disease

(2010) Ahmed Bawazeer et al.   OCULAR IMMUNOLOGY AND INFLAMMATION

Adalimumab safety in global clinical trials of patients with Crohnʼs disease

(2009) Jean-Frédéric Colombel et al.   INFLAMMATORY BOWEL DISEASES

Clinical characteristics of Behçet’s disease in China

(2009) Liao-Yuan Wang et al.   RHEUMATOLOGY INTERNATIONAL